Literature DB >> 30704685

Parkinson's Disease.

Stephen G Reich1, Joseph M Savitt2.   

Abstract

The diagnosis of Parkinson disease (PD) is based on the presence of bradykinesia and either resting tremor or rigidity and there should be no features from the history or examination to suggest an alternative cause of parkinsonism. In addition to the motor manifestations of PD, there is a long list of nonmotor symptoms, several of which occur before motor signs and are considered "prodromal" PD. These are classified as neuropsychiatric, autonomic, sleep, and sensory. There are many medical options for the treatment of PD but levodopa remains the mainstay. Deep brain stimulation and other advanced therapies are also available.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyskinesias; Levodopa; Parkinsonism; Parkinson’s disease; REM sleep behavioral disorder; Tremor

Mesh:

Substances:

Year:  2018        PMID: 30704685     DOI: 10.1016/j.mcna.2018.10.014

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  57 in total

Review 1.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

Review 2.  Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.

Authors:  Vasiliki Katsi; Ilias Papakonstantinou; Eirini Solomou; Alexios S Antonopoulos; Charalambos Vlachopoulos; Konstantinos Tsioufis
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

Review 3.  Vibrotactile biofeedback devices in Parkinson's disease: a narrative review.

Authors:  Helena R Gonçalves; Ana Margarida Rodrigues; Cristina P Santos
Journal:  Med Biol Eng Comput       Date:  2021-05-10       Impact factor: 2.602

4.  The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.

Authors:  Piniel Alphayo Kambey; Ma Chengcheng; Guo Xiaoxiao; Ayanlaja Abiola Abdulrahman; Kouminin Kanwore; Iqra Nadeem; Wu Jiao; Dianshuai Gao
Journal:  Metab Brain Dis       Date:  2021-01-28       Impact factor: 3.584

5.  Rotigotine Transdermal Patch: A Review in Parkinson's Disease.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2019-07       Impact factor: 5.749

6.  The influences of behavioral and psychological interventions on the neurological function and MMSE scores in Parkinson's disease patients.

Authors:  Aimin Luo; Shuming Zhong; Shunkai Lai; Yanbin Jia
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  Evidence-Based Recommendations for the Oral Health of Patients with Parkinson's Disease.

Authors:  Ana L C Martimbianco; Fabio C Prosdocimi; Camillo Anauate-Netto; Elaine M Dos Santos; Gustavo D Mendes; Yara D Fragoso
Journal:  Neurol Ther       Date:  2021-03-18

8.  Protective effects of baicalin in a Caenorhabditis elegans model of Parkinson's disease.

Authors:  Jing Ma; Ranran Wang; Ting Chen; Shaowei Jiang; Ajing Xu
Journal:  Toxicol Res (Camb)       Date:  2021-04-26       Impact factor: 3.524

Review 9.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

10.  Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis.

Authors:  Mangala Kumari; Premdass Ramdas; Ammu Kutty Radhakrishnan; Methil Kannan Kutty; Nagaraja Haleagrahara
Journal:  Nutrients       Date:  2021-05-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.